Silexion Therapeutics LTD (SLXN)
NASDAQ: SLXN
· Real-Time Price · USD
0.99
-0.01 (-1.00%)
At close: May 02, 2025, 3:59 PM
1.00
0.81%
After-hours: May 02, 2025, 05:50 PM EDT
-1.00% (1D)
| Bid | 0.98 |
| Market Cap | 8.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.44M |
| EPS (ttm) | -26.36 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.6 |
| Analyst | Buy |
| Ask | 1 |
| Volume | 159,507 |
| Avg. Volume (20D) | 4,932,546 |
| Open | 0.99 |
| Previous Close | 1.00 |
| Day's Range | 0.98 - 1.04 |
| 52-Week Range | 0.21 - 13.56 |
| Beta | 0.06 |
About SLXN
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 16, 2024
Employees 11
Stock Exchange NASDAQ
Ticker Symbol SLXN
Website https://silexion.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SLXN stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 404.08% from the latest price.
Stock Forecasts1 week ago
+46.51%
Sliexion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+30.63%
Silexion Therapeutics shares are trading higher after the company announced groundbreaking initial data from its systemic administration of SIL204 in orthotopic pancreatic cancer models.
